University of Illinois at Chicago
Chicago, Illinois, 60612, United States
NCT Number: NCT03948243
Human safety studies will be carried out to test whether red clover botanical dietary supplements used by peri- and post-menopausal women are safe to use with Food and Drug Administration (FDA)-approved drugs. To test this, a red clover dietary supplement (previously tested in women at the University of Illinois at Chicago without any harmful effects) will be given with four selected FDA-approved drugs to determine if the Licorice supplement can increase or decrease how these medications are absorbed, metabolized and excreted by the human body. Preclinical studies predict that the licorice supplement might affect the metabolism or break down of these probe drugs.
Looking for future studies?
Notify Me40 year–79 year
Female
Interventional
Phase 1
Chicago, Illinois, 60612, United States
At the start of a study, subjects will be administered low doses of a mixture of four FDA-approved drugs (caffeine, tolbutamide, dextromethorphan, and alprazolam), and serial blood samples will be drawn and analyzed for the concentration of each drug over time. Afterwards, participants will take the licorice dietary supplement twice daily for 14 days to allow for potential inhibition or induction of drug metabolizing enzymes and transporters. Thereafter, the same drugs will be taken again to obtain a second measure of drug concentrations in blood over time. Changes in the concentration-time curve values for each probe drug obtained before and after ingestion of the supplement would indicate that metabolism of the probe drugs is impacted by the licorice dietary supplement.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
Other names: G. glabra
probe substrate
Other names: CYP3A4/5 substrate
probe substrate
Other names: CYP1A2 substrate
probe substrate
Other names: CYP2C9 substrate
probe substrate
Other names: CYP2D6 substrate
Time frame: baseline and 14 days
Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate area under the (extrapolated) concentration-time curve to determine any changes compared to pre-intervention.
Time frame: baseline and 14 days
Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate apparent clearance of probe drug to determine any changes compared to pre-intervention.
Time frame: baseline and 14 days
Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate peak concentration of probe drug to determine any changes compared to pre-intervention.
Time frame: baseline and 14 days
Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate time for peak concentration of probe drug to determine any changes compared to pre-intervention.
Time frame: baseline and 14 days
Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate half-life of probe drug to determine any changes compared to pre-intervention.
University of Illinois at Chicago
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06726382
Drug Interactions, Food-drug Interaction
Helsinki, Finland
View Trial DetailsNCT06218979
Food-drug Interaction, Mental Disorders
Helsinki, Finland
View Trial DetailsNCT06211283
Food-drug Interaction
Toronto, Canada
View Trial DetailsNCT05533788
Food-drug Interaction, Health, Subjective
Taipei, Taiwan
View Trial Details